Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IEC 2021 | GABA suppressing drugs in epilepsy treatment

James Clement • 20 Aug 2021
IEC 2021
Epilepsy Bumetanide

James Clement, PhD, Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore, India, discusses the evidence supporting γ-Aminobutyric acid (GABA) suppressing drugs in epilepsy treatment. Dr Clement describes studies showing that bumetanide, a drug suppressing GABA activity, was able to restore the synaptic function in mouse models with autism and can be helpful in epilepsy treatment. This interview took place during the 34th International Epilepsy Congress, 2021.

More from James Clement

The next steps in autism treatment: gene therapy
0:46
The next steps in autism treatment: gene therapy
James Clement • 20 Aug 2021
Upcoming clinical trials for small molecules to treat autism spectrum disorder
1:45
Upcoming clinical trials for small molecules to treat autism spectrum disorder
James Clement • 20 Aug 2021
GABAergic signaling in autism spectrum disorders
1:56
GABAergic signaling in autism spectrum disorders
James Clement • 20 Aug 2021

Related Videos

Which emerging epilepsy therapies are likely to change clinical practice?
9:12
Which emerging epilepsy therapies are likely to change clinical practice?
William Alves Martins • 20 Oct 2026
Emerging gene therapies for Dravet syndrome and other DEEs
10:41
Emerging gene therapies for Dravet syndrome and other DEEs
William Alves Martins • 20 Oct 2026
Emerging precision therapies reshaping the antiseizure medication landscape in epilepsy
9:58
Emerging precision therapies reshaping the antiseizure medication landscape in epilepsy
William Alves Martins • 20 Oct 2026
Phase II/III POWER1: efficacy, safety and lessons learned for vormatrigine in epilepsy
8:05
Phase II/III POWER1: efficacy, safety and lessons learned for vormatrigine in epilepsy
William Alves Martins • 20 Oct 2026

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJNeurology is intended for healthcare professionals